Referred to the House Committee on Energy and Commerce.
The bill amends the Federal Food, Drug, and Cosmetic Act to authorize regulated importation of qualifying prescription drugs from Canada, the United Kingdom, EU member states, Switzerland, and potentially other countries. It creates a certification program for foreign pharmacies and wholesale distributors, requires labeling, testing, tracing, and reporting, permits individuals to import limited personal supplies with valid prescriptions, prohibits certain manufacturer anti-competitive actions, and establishes enforcement, suspension, and reporting requirements for HHS and GAO reviews.
Left emphasizes immediate access and price relief for insulin and biologics.
Relative to its intended legislative type, this bill is a substantive statutory redesign of existing law to authorize and regulate prescription drug importation, and it is drafted with considerable operational detail while delegating customary rulemaking and international coordination tasks to the Secretary.
The bill amends the Federal Food, Drug, and Cosmetic Act to authorize regulated importation of qualifying prescription drugs from Canada, the United Kingdom, EU member states, Switzerland, and potentially other countries.
It creates a certification program for foreign pharmacies and wholesale distributors, requires labeling, testing, tracing, and reporting, permits individuals to import limited personal supplies with valid prescriptions, prohibits certain manufacturer anti-competitive actions, and establishes enforcement, suspension, and reporting requirements for HHS and GAO reviews.
Offers concrete safety and oversight mechanisms appealing to some bipartisan sentiment, but significant stakeholder opposition and implementation complexity lower odds.
Relative to its intended legislative type, this bill is a substantive statutory redesign of existing law to authorize and regulate prescription drug importation, and it is drafted with considerable operational detail while delegating customary rulemaking and international coordination tasks to the Secretary.
Left emphasizes immediate access and price relief for insulin and biologics.
These are examples from the analysis, not a ranked list of the most-affected groups.
Left emphasizes immediate access and price relief for insulin and biologics.
Generally supportive.
The bill is seen as a practical mechanism to lower out-of-pocket drug costs and expand access, including for insulin and other high-cost biologics, while building regulatory safeguards.
Supporters will emphasize price relief and patient access, while urging strong implementation and enforcement.
Cautiously favorable if regulations demonstrate safety and measurable cost savings.
The centrist view values the bill's pragmatic, evidence-driven approach but wants clear implementation plans, adequate regulatory funding, and safeguards against unintended supply disruptions.
Skeptical to opposed.
Concerns center on increased federal intervention, potential safety risks from foreign supply, effects on pharmaceutical innovation and contracts, and expansion of regulatory obligations on manufacturers.
Some may approve personal waivers, but institutional importation is viewed warily.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Offers concrete safety and oversight mechanisms appealing to some bipartisan sentiment, but significant stakeholder opposition and implementation complexity lower odds.
The bill has not accumulated any surfaced votes yet.
Left emphasizes immediate access and price relief for insulin and biologics.
Offers concrete safety and oversight mechanisms appealing to some bipartisan sentiment, but significant stakeholder opposition and implemen…
Relative to its intended legislative type, this bill is a substantive statutory redesign of existing law to authorize and regulate prescription drug importation, and it is drafted with considerable operational detail wh…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.